Premium
Immune checkpoint B7‐H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer
Author(s) -
NunesXavier Caroline E.,
Kildal Wanja,
Kleppe Andreas,
Danielsen Håvard E.,
Wæhre Håkon,
Llarena Roberto,
Mælandsmo Gunhild M.,
Fodstad Øystein,
Pulido Rafael,
López José I.
Publication year - 2021
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.24180
Subject(s) - prostate cancer , medicine , prostatectomy , oncology , prostate , androgen receptor , immune checkpoint , cohort , adenocarcinoma , immunohistochemistry , cancer , prostate specific antigen , biochemical recurrence , immunotherapy
Background Novel immune checkpoint‐based immunotherapies may benefit specific groups of prostate cancer patients who are resistant to other treatments. Methods We analyzed by immunohistochemistry the expression of B7‐H3, PD‐L1/B7‐H1, and androgen receptor (AR) in tissue samples from 120 prostate adenocarcinoma patients treated with radical prostatectomy in Spain, and from 206 prostate adenocarcinoma patients treated with radical prostatectomy in Norway. Results B7‐H3 expression correlated positively with AR expression and was associated with biochemical recurrence in the Spanish cohort, but PD‐L1 expression correlated with neither of them. Findings for B7‐H3 were validated in the Norwegian cohort, where B7‐H3 expression correlated positively with Gleason grade, surgical margins, seminal vesicle invasion, and CAPRA‐S risk group, and was associated with clinical recurrence. High B7‐H3 expression in the Norwegian cohort was also consistent with positive AR expression. Conclusion These results suggest distinct clinical relevance of the two immune checkpoint proteins PD‐L1 and B7‐H3 in prostate cancer. Our findings highlight B7‐H3 as an actionable novel immune checkpoint protein in prostate cancer.